AEON Biopharma Appoints BOTOX® Therapeutic Head as President and Chief Executive Officer
May 13, 2019
NEWPORT BEACH, Calif., May 13, 2019 – ALPHAEON Corporation announced today that its Board of Directors has named Marc Forth as President and Chief Executive Officer of its newly established, wholly-owned subsidiary, AEON Biopharma, Inc. AEON Biopharma was established to independently pursue the rapidly growing, multi-billion-dollar, therapeutic toxin market. Therapeutic related applications represent greater than 60% of global neurotoxin segment revenues. Mr. Forth joins AEON Biopharma from Allergan, where he was Senior Vice President of Neurosciences, Urology and Medical Dermatology. Mr. Forth led, among other brands, BOTOX® Therapeutic, an organization with annual revenues of approximately $2 Billion.
Strathspey Crown Founder Publishes First Infinite Prime Number Prediction Methodology
March 21, 2019— Strathspey Crown LLC announces today that its Founder and Chairman, Robert E. Grant, identified the first Infinite Prime Number prediction pattern. The discovery was published yesterday on Cornell University’s www.arXiv.org titled: “Accurate and Infinite Prime Number Prediction from Novel Quasi-Prime Analytical Methodology.” The paper was co-authored by Physicist and Number Theorist Talal Ghannam PhD.